Market Place
Sourcing Support
Opna Bio to Present Data at ASH on BET Inhibitor in Myelofibrosis
13 Nov 2024 //
BUSINESSWIRE
Incyte Shares Atopic Dermatitis Patient Experiences
10 Oct 2024 //
BUSINESSWIRE
Incyte To Present Dermatology Data At EADV 2024 Congress
25 Sep 2024 //
BUSINESSWIRE
Ironwood spies new frontier for $1B drug in exploratory trial
29 Mar 2024 //
FIERCE BIOTECH
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream
10 Mar 2024 //
BUSINESSWIRE
Incyte defends Jakafi against competitor drugs, patent cliff
31 Oct 2023 //
FIERCE PHARMA
Incyte Announces New Data for Ruxolitinib in Children with Atopic Dermatitis
13 Oct 2023 //
BUSINESSWIRE
Data from Incyte Phase 3 Program Demonstrates Efficacy of with Opzelura
11 Oct 2023 //
BUSINESSWIRE
FDA Confirms Paragraph IV Patent Litigation for Ruxolitinib Phosphate Cream
21 Sep 2023 //
FDA
Incyte skin disease cream for children meets main goal in late-stage study
12 Jul 2023 //
REUTERS
Navtemadlin & Ruxolitinib Leads to SVR Benefit in TP53 Wild-Type Myelofibrosis
08 Jul 2023 //
ONCLIVE
MHRA Grants Marketing Authorisation for Opzelura for Non-Segmental Vitiligo
06 Jul 2023 //
BUSINESSWIRE
Karyopharm Initiates Pivotal Ph3 Study of XPO1 Inhibitor Selinexor & Ruxolitinib
28 Jun 2023 //
PR NEWSWIRE
Incyte`s Opzelura (Ruxolitinib) Receives Approval in Europe
22 Jun 2023 //
EMA
Zilurgisertib With or Without Ruxolitinib Shows Tolerability in Anemic Myelofibrosis
13 Jun 2023 //
ONCLIVE
Blood cancer trial finds ruxolitinib better than current treatments
05 May 2023 //
CLINICAL TRIALS ARENA
Incyte Announces Results from SCRATCH-AD TrialOpzelura® (ruxolitinib) Cream
01 May 2023 //
BUSINESSWIRE
Incyte Biosciences Opzelura Receives Approral in Europe
20 Apr 2023 //
EMA
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data
18 Apr 2023 //
PR NEWSWIRE
Incyte hit by CRL on extended-release JAK tablets
25 Mar 2023 //
ENDPTS
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program
18 Mar 2023 //
BUSINESSWIRE
Incyte stops PhIII trial for PI3K inhibitor after primary endpoint failure
07 Mar 2023 //
ENDPTS
Incyte to discontinue late-stage trial for bone marrow cancer drug combination
04 Mar 2023 //
REUTERS
Incyte Provides Update on PIII LIMBER-304 Study of Parsaclisib and Ruxolitinib
03 Mar 2023 //
BUSINESSWIRE
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream for Vitiligo
24 Feb 2023 //
BUSINESSWIRE
Imago doses first subject in Phase II myelofibrosis treatment trial
22 Dec 2022 //
CLINICALTRIALSARENA
Imago Announces First Participant Dosed Ph 2 Study of Bomedemstat
20 Dec 2022 //
GLOBENEWSWIRE
Imago BioSciences Presents Positive Data from Ongoing Ph2 Study of Bomedemstat
12 Dec 2022 //
GLOBENEWSWIRE
Ajax Presents Preclinical Data on AJ1-10502 at American Society of Hematology
11 Dec 2022 //
BUSINESSWIRE
AltruBio Presents Data from Phase 1b Study Evaluating ALTB-168 in Patients
10 Dec 2022 //
GLOBENEWSWIRE
AbbVie Presents Data at ASH for Investigational Navitoclax With Ruxolitinib
10 Dec 2022 //
PRNEWSWIRE
Incyte Announces Data from LIMBER Studies Evaluating Combination Treatments
10 Dec 2022 //
BUSINESSWIRE
Leo`s JAK inhibitor cream posts positive results for hand eczema
06 Dec 2022 //
FIERCEPHARMA
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib
02 Dec 2022 //
BUSINESSWIRE
Despite recent progress,Incyte still far off from pricing goal eczema launch
02 Nov 2022 //
FIERCEPHARMA
PIII Data Shows Improvements in Repigmentation Published in Journal of Medicine
19 Oct 2022 //
BUSINESSWIRE
FDA declines to free MaaT`s microbiome drug from clinical hold after a year
11 Aug 2022 //
FIERCE BIOTECH
Incyte plots ambitious campaign for new Opzelura use
05 Aug 2022 //
FIERCEPHARMA
Incyte Announces U.S. FDA Approval of Opzelura Cream for Vitiligo
18 Jul 2022 //
BUSINESSWIRE
FDA Clears Cellenkos` IND Application for CK0804
16 Jun 2022 //
PRNEWSWIRE
Novartis receives EC approval for Jakavi in GvHD
05 May 2022 //
NOVARTIS
Incyte Bags EC Approval of Jakavi for Acute and Chronic GvHD
05 May 2022 //
BUSINESSWIRE
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream
28 Apr 2022 //
BUSINESSWIRE
Complaint reveals quality woes with Incyte`s eczema cream—again
20 Apr 2022 //
FIERCEPHARMA
Ruxolitinib significantly reduces disease and improves quality of life
29 Mar 2022 //
PRESS RELEASE
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial for MaaT013
28 Mar 2022 //
BUSINESSWIRE
Incyte Shows 52-Week Data From Phase 3 TRuE-V Program for Ruxolitinib Cream
26 Mar 2022 //
BUSINESSWIRE
Incyte Announces Positive CHMP Opinion for Ruxolitinib in GvHD
25 Mar 2022 //
BUSINESSWIRE
FDA orders Incyte to hold up yet again in the hunt for blockbuster franchise
15 Mar 2022 //
ENDPTS
Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream
14 Dec 2021 //
BUSINESSWIRE
Even as topical, shaking JAK concerns may be tough for Opzelura
12 Nov 2021 //
FIERCEPHARMA
Incyte`s eczema cream Opzelura combats payer hurdles: exec
03 Nov 2021 //
FIERCEPHARMA
Jakafi maker Incyte channels blood testing anxiety in awareness ads
12 Oct 2021 //
FIERCEPHARMA
Incyte trial reveals encouraging results for patients with vitiligo
06 Oct 2021 //
PHARMAFILE
Incyte: Results From Phase 3 Study Evaluating Ruxolitinib Cream in Vitiligo
02 Oct 2021 //
BUSINESSWIRE
Incyte turns to in-licensing
27 Sep 2021 //
EVALUATE
Incyte and Seagen face tricky launches
23 Sep 2021 //
EVALUATE
FDA Approves Incyte`s Jakafi for Treatment of Chronic GVHD
22 Sep 2021 //
BUSINESSWIRE
FDA approves Incyte`s eczema cream with boxed warnings
22 Sep 2021 //
REUTERS
